



## DECLARATION OF CONFORMITY

**Manufacturer:** **Invivoscribe Inc.**  
10222 Barnes Canyon Rd. Bldg. 1  
San Diego, California 92121  
United States of America

**Authorized Representative:** **Invivoscribe Technologies, SARL**  
c/o Ficorec Domiciliation Services  
132, Boulevard Michelet  
Hall Nord – 5ème étage  
13008 Marseille  
FRANCE

**UK Responsible Person:** Gillian Pawlowsky Ltd.  
272 Bath Street  
Glasgow G2 4JR  
Scotland UK

**Family Name:** Software

**Device Trade Name:** LymphoTrack® Dx Software – MiSeq®

Catalog #	Device	Version
9-500-0009	LymphoTrack® Dx Software – MiSeq®	2.4.x

I, the undersigned, hereby declare that the *in-vitro* diagnostic medical devices specified above conform to the European Directive 98/79/EC, *In vitro* Diagnostic Medical Device Directive, Annex III.

I, the undersigned, hereby declare that the *in-vitro* diagnostic medical devices specified above conform to the Part IV of the UK Medical Device Regulations 2002, Annex III (as modified by Part III of Schedule 2A to the UK MDR 2002).

\*Date of Validity: 10 Oct 2023

By: Jason Gerhold

Jason Gerhold  
Global Director of Quality, Regulatory and Clinical Affairs  
Invivoscribe, Inc.  
10222 Barnes Canyon Rd. Bldg. 1  
San Diego, California 92121  
USA

\*Originally signed on 05/18/2022, no significant changes have occurred to the product since that date